Gerd Bendas

Bonn, NW 53121, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications

Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis.

Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis.

Journal: ACS chemical biology
Published: March 31, 2026

Fully Synthetic Non-Carbohydrate Heparin Mimetics-Perspectives for Therapeutic Anticoagulation and Beyond?

Fully Synthetic Non-Carbohydrate Heparin Mimetics-Perspectives for Therapeutic Anticoagulation and Beyond?

Journal: Archiv der Pharmazie
Published: January 29, 2026

Shear-Activated von Willebrand Factor Captures Extracellular Vesicles to Promote Platelet Activation and Metastasis.

Shear-Activated von Willebrand Factor Captures Extracellular Vesicles to Promote Platelet Activation and Metastasis.

Journal: Journal of extracellular vesicles
Published: November 13, 2025

Comparing Heparin and Heparin Mimetics in Targeting Immunomodulatory Proteins from Platelets to Activate T Cell-Dependent Immune Response in Oncology.

Comparing Heparin and Heparin Mimetics in Targeting Immunomodulatory Proteins from Platelets to Activate T Cell-Dependent Immune Response in Oncology.

Journal: ACS pharmacology & translational science
Published: October 30, 2025

Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders.

Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders.

Journal: Journal of medicinal chemistry
Published: June 18, 2025

Target Engagement Studies and Kinetic Live-Cell Degradation Assays Enable the Systematic Characterization of Histone Deacetylase 6 Degraders.

Target Engagement Studies and Kinetic Live-Cell Degradation Assays Enable the Systematic Characterization of Histone Deacetylase 6 Degraders.

Journal: ACS pharmacology & translational science
Published: April 04, 2025

Increased efficacy of PARP inhibitors against cisplatin-sensitive and -resistant ovarian cancer cells mediated via ATR and ATM inhibition.

Increased efficacy of PARP inhibitors against cisplatin-sensitive and -resistant ovarian cancer cells mediated via ATR and ATM inhibition.

Journal: Cell death discovery
Published: March 24, 2025

A Novel Series of Synthetic Heparin-Mimetics-Itaconic Acid-Containing Copolymers for Targeting Tumor Cell Coagulability and Metastasis.

A Novel Series of Synthetic Heparin-Mimetics-Itaconic Acid-Containing Copolymers for Targeting Tumor Cell Coagulability and Metastasis.

Journal: Macromolecular bioscience
Published: December 19, 2024

Modulating Immune Responses: The Double-Edged Sword of Platelet CD40L.

Modulating Immune Responses: The Double-Edged Sword of Platelet CD40L.

Journal: Seminars in thrombosis and hemostasis
Published: October 08, 2024

Pyrazinyl-Substituted Aminoazoles as Covalent Inhibitors of Thrombin: Synthesis, Structure, and Anticoagulant Properties.

Pyrazinyl-Substituted Aminoazoles as Covalent Inhibitors of Thrombin: Synthesis, Structure, and Anticoagulant Properties.

Journal: ACS pharmacology & translational science
Published: August 26, 2024

Epigenetic Targeting of Heparan Sulfate 3-O- and 6-O-Sulfation in Breast Cancer Cells: Prospects for Attenuating Prothrombotic Tumor Cell Activities.

Epigenetic Targeting of Heparan Sulfate 3-O- and 6-O-Sulfation in Breast Cancer Cells: Prospects for Attenuating Prothrombotic Tumor Cell Activities.

Journal: ACS pharmacology & translational science
Published: May 21, 2024

Diversity Oriented Synthesis of Novel Xanthones Reveal Potent Doxorubicin-Inspired Analogs.

Diversity Oriented Synthesis of Novel Xanthones Reveal Potent Doxorubicin-Inspired Analogs.

Journal: ChemMedChem
Published: January 30, 2024
Showing 1-12 of 80

Last Updated: 09/26/2026